FDA panel with industry ties to review peptide injection safety in July

The FDA will review the safety of several peptide injections in July. A new advisory panel has been formed to assess these products, which are widely marketed online for muscle growth, injury recovery, and anti-ageing. The panel’s members include professionals with financial links to the peptide industry. Previous FDA panels consisted of independent academics and researchers with no ties to industry. This time, the group includes doctors and pharmacists who profit from peptide sales or related therapies.

Among them is Dr. Haleem Mohammed, who operates clinics offering peptide injections and other unapproved treatments. Dr. Gabriel Alizaidy also promotes peptides and charges for advice on sourcing them. Tennessee state senator and pharmacist Bobby Harshbarger, another panel member, has connections to the same sector.

Peptides like BPC-157 and TB-500 are often produced by compounding pharmacies rather than traditional drug manufacturers. The FDA has already flagged safety risks associated with these substances. Despite the lack of strong evidence, they continue to be sold online with claims of health and cosmetic benefits. The FDA’s July review will determine whether these peptides remain available. Critics, including Kennedy and his allies, have long highlighted conflicts of interest in government panels. The inclusion of industry-linked experts has renewed these concerns.